Safeguarding public health



M&S.good practices and next steps

Rob Hemmings



No intention to lecture this audience on 'good practice'



Different standards for different exercises (L,M,H) Standard should be high!

- Assumptions (not only mathematical)Model building rationale
- Model testing
- Inference
- Sensitivity analyses / Challenge assumptions
- Reporting

Detail of regulatory response might be vary according to impact



Assumptions

· Formulating, challenging

Avoiding selection bias

Avoiding 'conflict of interest' bias



Communication

• To whom?

Adding objectivity to inform a better subjective decision

Based on sound scientific understanding

How often is this possible?



Pre-specification

- Before analysis
- Before data?
- Contradicts modelling?

Guidance

- Adequacy of pop PK reporting for all M&S?
- Possible?
- Helpful?



Building experience

Building trust

Safety and efficacy

Changes in regulatory assessment process ("scrutiny"), but not changes in regulatory standards

Next steps



Clarify options for discussion

- EMA / CHMP Scientific Advice
 - Product specific
 - Broad scope
 - Qualification process
 - Parallel FDA
 - Parallel HTA
- EMA / Innovation Task Force meetings
- National SA (Product specific, broad scope, parallel HTA)

Next steps



Advice on advice

- Pre-submission meetings with EMA
- Ask the right questions
- · Provide the right background
- Ask clarification / follow-up

Next steps



Workshop report
Discussion at EMA / CHMP
What to do?

- Guidance?
- Working Party?
- Collaborations academia, other RA